At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 445 enrolled

Drug / intervention

Oxymetazoline HCL Cream 1.0% +1 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02132117

NCT02132117Phase 3Completed

Compare CT.gov

Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea

Allergan·interventional·Posted May 7, 2014·Updated Nov 18, 2019

In Brief

A Phase 3 clinical trial evaluating Oxymetazoline HCL Cream 1.0% and Vehicle to Oxymetazoline HCL Cream for Erythema and Rosacea. Completed, enrolled 445 participants across 1 site.

Detailed Summary

This study will evaluate the safety and efficacy of oxymetazoline hydrochloride (HCl) cream 1.0% (AGN-199201) once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsErythema, Rosacea

CountriesUnited States

Collaborators--

Timeline

Phase 3CompletedFinished

201520162017201820192020202120222023202420252026

First PostedMay 2014

Enrollment StartJun 2014

Primary CompletionApr 2015

Study CompletionMay 2015

TodayJul 2026

First PostedMay 7, 2014

Enrollment StartJun 1, 2014

Primary CompletionApr 1, 2015

Study CompletionMay 1, 2015

TodayJul 2, 2026

Enrollment to primary: 10 monthsPosted 12.2 years ago

Interventions

Oxymetazoline HCL Cream 1.0%drug

Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 29 days.

Vehicle to Oxymetazoline HCL Creamdrug

Vehicle to Oxymetazoline HCL Cream (AGN-199201) applied to the face once daily for 29 days.